MAP2K7 and acute myeloid leukemia: A combination treatment strategy, given the known resistance that can occur with MEK inhibition, via AKT inhibition (PI3K/AKT pathway), in addition to MEK inhibition, has been studied in a phase 2 trial; the combination of GSK2141795 (pan-AKT kinase inhibitor) with MEK inhibition did not result in any complete remissions in a cohort of RAS-mutated AML patients [189].